CA2430124C - Lactam compounds and pharmaceutical use thereof - Google Patents

Lactam compounds and pharmaceutical use thereof Download PDF

Info

Publication number
CA2430124C
CA2430124C CA2430124A CA2430124A CA2430124C CA 2430124 C CA2430124 C CA 2430124C CA 2430124 A CA2430124 A CA 2430124A CA 2430124 A CA2430124 A CA 2430124A CA 2430124 C CA2430124 C CA 2430124C
Authority
CA
Canada
Prior art keywords
group
substituent
groups
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2430124A
Other languages
English (en)
French (fr)
Other versions
CA2430124A1 (en
Inventor
Yukio Iino
Takao Ikenoue
Nobuo Kondo
Hiroyuki Matsueda
Toshihiro Hatanaka
Ryusuke Hirama
Yoko Masuzawa
Fumio Ohta
Akiyo Yamazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of CA2430124A1 publication Critical patent/CA2430124A1/en
Application granted granted Critical
Publication of CA2430124C publication Critical patent/CA2430124C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
CA2430124A 2000-12-01 2001-11-29 Lactam compounds and pharmaceutical use thereof Expired - Fee Related CA2430124C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000367175 2000-12-01
JP2000-367175 2000-12-01
PCT/JP2001/010435 WO2002044180A1 (en) 2000-12-01 2001-11-29 Lactam compounds and medicinal use thereof

Publications (2)

Publication Number Publication Date
CA2430124A1 CA2430124A1 (en) 2002-06-06
CA2430124C true CA2430124C (en) 2011-01-11

Family

ID=18837660

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2430124A Expired - Fee Related CA2430124C (en) 2000-12-01 2001-11-29 Lactam compounds and pharmaceutical use thereof

Country Status (26)

Country Link
US (3) US7153850B2 (cg-RX-API-DMAC7.html)
EP (1) EP1346993B1 (cg-RX-API-DMAC7.html)
JP (2) JP3826400B2 (cg-RX-API-DMAC7.html)
KR (1) KR100826818B1 (cg-RX-API-DMAC7.html)
CN (2) CN1269818C (cg-RX-API-DMAC7.html)
AT (1) ATE446297T1 (cg-RX-API-DMAC7.html)
AU (3) AU1850202A (cg-RX-API-DMAC7.html)
BG (1) BG107857A (cg-RX-API-DMAC7.html)
BR (1) BR0115852A (cg-RX-API-DMAC7.html)
CA (1) CA2430124C (cg-RX-API-DMAC7.html)
CZ (1) CZ20031520A3 (cg-RX-API-DMAC7.html)
DE (1) DE60140270D1 (cg-RX-API-DMAC7.html)
ES (1) ES2331299T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0400806A3 (cg-RX-API-DMAC7.html)
IL (1) IL156158A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03004876A (cg-RX-API-DMAC7.html)
NO (1) NO325401B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ526164A (cg-RX-API-DMAC7.html)
PL (1) PL362835A1 (cg-RX-API-DMAC7.html)
RU (1) RU2287530C2 (cg-RX-API-DMAC7.html)
SK (1) SK6582003A3 (cg-RX-API-DMAC7.html)
TW (1) TWI241302B (cg-RX-API-DMAC7.html)
UA (1) UA76969C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002044180A1 (cg-RX-API-DMAC7.html)
YU (1) YU42603A (cg-RX-API-DMAC7.html)
ZA (1) ZA200304100B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI241302B (en) * 2000-12-01 2005-10-11 Ajinomoto Kk Lactam compounds and pharmaceutical use thereof
MXPA05008363A (es) 2003-02-07 2005-12-06 Ajinomoto Kk Agentes terapeuticos para diabetes.
WO2005042536A1 (ja) * 2003-10-31 2005-05-12 Ajinomoto Co., Inc. 複素環を有する新規縮合多環式化合物及びその医薬用途
CA2553329A1 (en) 2004-01-14 2005-07-28 Ajinomoto Co., Inc. New fused polycyclic compounds
CN101899049A (zh) * 2004-10-13 2010-12-01 霍夫曼-拉罗奇有限公司 二取代吡唑并苯并二氮杂*类
JP5056412B2 (ja) 2005-04-28 2012-10-24 味の素株式会社 新規ラクタム化合物
EP2157092A4 (en) * 2007-04-11 2011-04-13 Ajinomoto Kk Remedy for diabetes
WO2008136394A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の製造方法及びその製造中間体
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008139575A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. 経口投与用製剤
CN101619041B (zh) * 2008-07-02 2012-07-04 重庆华邦制药股份有限公司 一种二酮基含氮环化合物的合成方法及其中间体
JP2012180283A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
JP2012180282A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
EP3238723B1 (en) * 2014-12-22 2020-02-05 EA Pharma Co., Ltd. Drug for treating disorders of corneal epithelium
WO2017127306A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
TWI820289B (zh) * 2019-01-23 2023-11-01 醣解生醫股份有限公司 β-內醯胺類化合物或其鹽於長效預防或治療葡萄糖代謝失調之用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US48847A (en) * 1865-07-18 Improvement in vessels for reception and transportation of night-soil
US189597A (en) * 1877-04-17 Improvement in portable wash-stands
GB8720414D0 (en) * 1987-08-28 1987-10-07 Roussel Lab Ltd Chemical compounds
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
ES2229523T3 (es) 1997-07-30 2005-04-16 Wyeth Agonistas triciclicos de la vasopresina.
JP4204657B2 (ja) 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
TWI241302B (en) * 2000-12-01 2005-10-11 Ajinomoto Kk Lactam compounds and pharmaceutical use thereof
MXPA05008363A (es) * 2003-02-07 2005-12-06 Ajinomoto Kk Agentes terapeuticos para diabetes.

Also Published As

Publication number Publication date
HUP0400806A2 (hu) 2004-07-28
NO325401B1 (no) 2008-04-21
PL362835A1 (en) 2004-11-02
ATE446297T1 (de) 2009-11-15
SK6582003A3 (en) 2003-09-11
CZ20031520A3 (cs) 2003-10-15
US7326701B2 (en) 2008-02-05
IL156158A0 (en) 2003-12-23
AU2002218502B2 (en) 2006-09-21
US7153850B2 (en) 2006-12-26
JPWO2002044180A1 (ja) 2004-04-02
CN1911915A (zh) 2007-02-14
US20040048847A1 (en) 2004-03-11
YU42603A (sh) 2006-03-03
KR100826818B1 (ko) 2008-05-02
NO20032439L (no) 2003-07-18
AU2006241377A1 (en) 2006-12-14
UA76969C2 (en) 2006-10-16
NO20032439D0 (no) 2003-05-28
US7632830B2 (en) 2009-12-15
AU1850202A (en) 2002-06-11
US20080096862A1 (en) 2008-04-24
CA2430124A1 (en) 2002-06-06
JP4505753B2 (ja) 2010-07-21
WO2002044180A1 (en) 2002-06-06
MXPA03004876A (es) 2004-01-27
BG107857A (bg) 2004-06-30
EP1346993A4 (en) 2005-12-21
CN100577651C (zh) 2010-01-06
EP1346993B1 (en) 2009-10-21
HUP0400806A3 (en) 2007-11-28
ZA200304100B (en) 2004-08-22
KR20030051893A (ko) 2003-06-25
ES2331299T3 (es) 2009-12-29
CN1487940A (zh) 2004-04-07
NZ526164A (en) 2004-09-24
CN1269818C (zh) 2006-08-16
JP3826400B2 (ja) 2006-09-27
US20060189597A1 (en) 2006-08-24
TWI241302B (en) 2005-10-11
RU2287530C2 (ru) 2006-11-20
EP1346993A1 (en) 2003-09-24
DE60140270D1 (de) 2009-12-03
BR0115852A (pt) 2003-12-23
JP2006213732A (ja) 2006-08-17
AU2006241377B2 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
US7632830B2 (en) Lactam compounds and pharmaceutical use thereof
TWI716458B (zh) γ-羥基丁酸的前藥及其組合物和用途
CN102408429A (zh) 抑制醛甾酮合酶和芳香酶的稠合咪唑并衍生物
KR102442536B1 (ko) 리나글립틴 결정형 및 이의 제조방법
HU229551B1 (hu) Mikroszóma triglicerid transzfer protein (MTP) és/vagy apolipoprotein B(APO B) kiválasztás inhibitorokként alkalmazható triamiddal helyettesített indol-, benzofurán- és benzotiofén-származékok
WO2016127916A1 (zh) 作为长效dpp-iv抑制剂的取代的氨基六元饱和杂脂环类
BR112021015951A2 (pt) Composto de pirimidinil-3,8-diazabiciclo[3.2.1]octanilmetanona cristalina e uso do mesmo
CN116178373B (zh) 非甾体抗炎药和gs-441524的二联体化合物及其制备方法与用途
JPH0611739B2 (ja) N―[6―メトキシ―5―(パーフルオロアルキル)―1―ナフトイル―n―メチルグリシンおよびチオナフトイル類似体
CN114423775B (zh) 一类芳基葡糖苷衍生物及其制备方法和应用
EP1707567A1 (en) Novel fused-ring compound
ES3029434T3 (en) A fxr small molecule agonist, the preparation and use thereof
CN114315830A (zh) Fxr小分子激动剂及其制备方法和用途
US20260001833A1 (en) Compounds, compositions, and methods for reducing production of trimethylamine
CN119241545A (zh) 苦参碱三环衍生物及其在制备治疗肝纤维化的药物中的应用
US20230295141A1 (en) Fxr small molecule agonist, the preparation and use thereof
CN102358731A (zh) 2-取代-6,7-二甲氧基四氢异喹啉衍生物,其制备方法,药物组合物及其用途
CN119745849A (zh) 双酰胺姜黄素类化合物在制备氧化应激损伤保护药物中的应用
CN120943796A (zh) 一种共价小分子化合物及其应用和药物组合物
HK1236935B (en) Substituted amino six-membered saturated heterocyclic fat used as long-acting dpp-iv inhibitor

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20121129